Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.
about
Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary ImmunodeficienciesOxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus ErythematosusmTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and agingT-cell metabolism in autoimmune disease.Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome.T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.Programmed cell death 1 and Helios distinguish TCR-αβ+ double-negative (CD4-CD8-) T cells that derive from self-reactive CD8 T cellsComprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycinAttenuation of AMPK signaling by ROQUIN promotes T follicular helper cell formation.Establishing a tree shrew model of systemic lupus erythematosus and cell transplantation treatment.Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.Metabolic Factors that Contribute to Lupus PathogenesisActivation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.Th17 cells in autoimmune diseases.Metabolism of murine TH 17 cells: Impact on cell fate and functionROQUIN signalling pathways in innate and adaptive immunity.T cells and IL-17 in lupus nephritis.T cells in Systemic Lupus Erythematosus.Immune Cell Metabolism in Systemic Lupus Erythematosus.T cells and autoimmune kidney disease.Immunometabolism in systemic lupus erythematosus.Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.PTENtiating autoimmunity through Treg cell deregulation.The mTORC1-4E-BP-eIF4E axis controls de novo Bcl6 protein synthesis in T cells and systemic autoimmunity.Functional and Phenotypic Plasticity of CD4(+) T Cell Subsets.Association between toll-like receptor 6 expression and auxiliary T cells in the peripheral blood of pediatric patients with allergic purpura.Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus.Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.Amino Acid Catabolism in Multiple Sclerosis Affects Immune Homeostasis.Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.Biotin Deficiency Induces Th1- and Th17-Mediated Proinflammatory Responses in Human CD4+ T Lymphocytes via Activation of the mTOR Signaling Pathway.mTOR Regulation of Glycolytic Metabolism in T Cells
P2860
Q28066193-F6BE4469-BDEC-41AA-BF64-326C1B372A83Q28071300-C281820A-C769-48BA-96FE-F195DED0DD10Q28081442-87A2027B-254D-4C60-A3A5-793921BE53D8Q35071556-D04A5BDF-F63F-4D44-86F9-EC0591B1EF1BQ35732790-2A18B341-1673-40E9-B905-886F05B846ECQ35836112-9665DDA8-9F19-47F1-84DD-334E209BFF36Q35856318-0D81A4CD-1B3F-4D6F-819A-66B6763CD975Q36024179-F4944722-AC58-4E90-8421-84154F661091Q36473888-3078FE08-A095-4366-A32B-41235DD4DEF1Q37199240-B46CA7A2-1A8A-449A-8C18-1A6D6F913613Q37372436-855C5DC6-5B26-4895-B945-03CA99E24D18Q37612885-4992830D-6884-48BB-B0EF-338088DE2697Q37649641-748FE669-B959-4411-8E84-0C8E24CD9C26Q37649687-A5CE7266-5DF4-454F-863C-500EDA4A2CA5Q37710586-6C33234D-4188-453A-9FCF-01F1DE182458Q38344543-1A1B86B3-A4FB-4430-8CA0-989893C2960CQ38439401-62619391-733A-4AF5-A6CF-6548672F289DQ38802693-B0CD2CB6-E9F2-4686-9612-CE84C3673BD4Q38816316-96C8F1C4-1A63-4180-B76D-E1FBCEBB70F8Q38956350-6652674D-9B78-4897-9559-50B44810FCEFQ38973345-605D238F-98BE-4B6B-8B5B-C34D3B55F271Q39175811-9D53E455-A015-4023-8006-8F02CDC6DF35Q39209701-F5BBCB02-B32C-482D-A44E-99D6769F51D7Q39379152-6E2D2D5F-ACA1-4B52-A18D-DC74D48C040EQ41234039-4574D25A-2FEB-4AF3-99FD-D6DA97C3AB25Q41423362-BAC77C43-3A2B-467D-95E6-886378BC655CQ43184369-CB234BA6-E0AF-422A-941E-5F332C2BA45AQ43244117-406E8866-B5EC-4E6C-80EB-16FA425E4D14Q47133379-6FB473FF-D735-4656-A935-57E220BB694EQ47574467-5F9472FA-B4F8-4D3C-91BF-C47D5E639FF2Q50068095-ABDB9FC4-7894-4CBD-AD31-F6243783C3DCQ51165149-BC3878DF-1AC0-40BA-B9FD-339F8F8AC1D8Q55096330-A040E7CA-8310-4629-B4D9-14FE0E5D8DDBQ55163735-A6D1340B-5548-470F-804D-837F323480ABQ55421717-CD4A91D5-D873-4CC7-9DCF-5B5A9323C3DFQ57491938-280CD948-6581-46ED-B827-A8E2C540C8BF
P2860
Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@ast
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@en
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@nl
type
label
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@ast
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@en
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@nl
prefLabel
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@ast
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@en
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@nl
P2860
P356
P1476
Mechanistic target of rapamyci ...... systemic lupus erythematosus.
@en
P2093
Hiroshi Kato
P2860
P304
P356
10.4049/JIMMUNOL.1301859
P407
P50
P577
2014-03-28T00:00:00Z